1988JAMARequires access

Occasional use of marijuana

R. H. Schwartz

Open publisher page 0 citations

Abstract

In Reply. — In response to Dr Goldstein, our study was a comparison of the tolerability and lipid-lowering effects of lovastatin and cholestyramine, so that our conclusion that lovastatin is more effective than cholestyramine applies only to the effects of the two drugs on lipids and lipoproteins, in particular the primary variables total and low-density lipoprotein (LDL) cholesterol. On this basis, 40 mg of lovastatin twice a day was approximately twice as effective as 12 g of cholestyramine twice a day, producing mean reductions in total and LDL-cholesterol of 34% and 42%, respectively, compared with 17% and 23% for cholestyramine. We agree that the ultimate value of lipid-lowering agents should be based on their effects on artherosclerosis. Several clinical trials to examine the effects of lovastatin and the closely related simvastatin on coronary lesion progression and coronary event rates are under way or about to begin. Although the results of

About this research paper

What this paper is about

In Reply. — In response to Dr Goldstein, our study was a comparison of the tolerability and lipid-lowering effects of lovastatin and cholestyramine, so that our conclusion that lovastatin is more effective than cholestyramine applies only to the effects of the two drugs on lipids and lipoproteins, in particular the primary variables total and low-density lipoprotein (LDL) cholesterol. On this basis, 40 mg of lovastatin twice a day was approximately twice as effective as 12 g of cholestyramine twice a day, producing mean reductions in total and LDL-cholesterol of 34% and 42%, respectively, compared with 17% and 23% for cholestyramine. We agree that the ultimate value of lipid-lowering agents should be based on their effects on artherosclerosis. Several clinical trials to examine the effects of lovastatin and the closely related simvastatin on coronary lesion progression and coronary event rates are under way or about to begin. Although the results of

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In Reply. — In response to Dr Goldstein, our study was a comparison of the tolerability and lipid-lowering effects of lovastatin and cholestyramine, so that our conclusion that lovastatin is more effective than cholestyramine applies only to the effects of the two drugs on lipids and lipoproteins, in particular the primary variables total and low-density lipoprotein (LDL) cholesterol. On this basis, 40 mg of lovastatin twice a day was approximately twice as effective as 12 g of cholestyramine twice a day, producing mean reductions in total and LDL-cholesterol of 34% and 42%, respectively, compared with 17% and 23% for cholestyramine. We agree that the ultimate value of lipid-lowering agents should be based on their effects on artherosclerosis. Several clinical trials to examine the effects of lovastatin and the closely related simvastatin on coronary lesion progression and coronary event rates are under way or about to begin. Although the results of

Key concepts: Lovastatin, Cholestyramine, Medicine, Simvastatin, Tolerability, Cholesterol, Internal medicine, Cholesterol lowering

Related papers

Back to paper searchBrowse research topicsOriginal source
Occasional use of marijuana — Research Paper | ScholarLens